Mohammad H. Ghalib

431 total citations
19 papers, 336 citations indexed

About

Mohammad H. Ghalib is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Mohammad H. Ghalib has authored 19 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Cancer Research and 5 papers in Genetics. Recurrent topics in Mohammad H. Ghalib's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Genomics and Diagnostics (5 papers). Mohammad H. Ghalib is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer Genomics and Diagnostics (5 papers). Mohammad H. Ghalib collaborates with scholars based in United States, Spain and Australia. Mohammad H. Ghalib's co-authors include Sanjay Goel, Imran Chaudhary, Radhashree Maitra, Umang Swami, Matthew Coffey, Sridhar Mani, George M. Gill, Mark H. Einstein, K.L. Mettinger and Kavita Desai and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics and Gynecologic Oncology.

In The Last Decade

Mohammad H. Ghalib

16 papers receiving 325 citations

Peers

Countries citing papers authored by Mohammad H. Ghalib

Since Specialization

Citations

This map shows the geographic impact of Mohammad H. Ghalib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad H. Ghalib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad H. Ghalib more than expected).

Fields of papers citing papers by Mohammad H. Ghalib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad H. Ghalib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad H. Ghalib. The network helps show where Mohammad H. Ghalib may publish in the future.

Co-authorship network of co-authors of Mohammad H. Ghalib

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad H. Ghalib. A scholar is included among the top collaborators of Mohammad H. Ghalib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad H. Ghalib. Mohammad H. Ghalib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials 2024 ·JAMA Network Open ·Sanjay Goel, Abdissa Negassa, Mohammad H. Ghalib, Imran Chaudhary, Kavita Desai, Umang Shah, Umang Swami, (unknown), Radhashree Maitra, Sridhar Mani	0
2	A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors 2024 ·Investigational New Drugs ·Mohammad H. Ghalib, Mariano Provencio, Maria J. de Miguel, Virginia Calvo, Imran Chaudhary, M Bakri Hammami, (unknown), Radhashree Maitra, Sara Martínez, Carmen Kahatt, (unknown), Salvador Fudio, Sanjay Goel	0
3	Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS -Mutated Colorectal Cancer 2020 ·Molecular Cancer Therapeutics ·Sanjay Goel, Allyson J. Ocean, (unknown), Mohammad H. Ghalib, Imran Chaudhary, Umang Shah, (unknown), (unknown), Matthew Coffey, Radhashree Maitra	25
4	Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials 2018 ·Investigational New Drugs ·Audrey E. Kam, Gopichand Pendurti, Umang Shah, Mohammad H. Ghalib, Imran Chaudhary, (unknown), Lakshmi Rajdev, Andreas Kaubisch, Santiago Aparo, Ioannis Mantzaris, Sanjay Goel	6
5	Hyperlipidemia secondary to acitretin therapy for lamellar ichthyosis associated with a NIPAL4 mutation improves on a plant-based diet and relapses on a standard Western diet 2018 ·Clinical Nutrition ESPEN ·(unknown), Daniele Massera, Mohammad H. Ghalib, Robert Marion, (unknown), Steven R. Cohen, Robert J. Ostfeld	0
6	Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer 2017 ·Clinical Colorectal Cancer ·Sanjay Goel, Abdissa Negassa, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Umang Shah, Imran Chaudhary, Mohammad H. Ghalib, Lakshmi Rajdev, Andreas Kaubisch, (unknown), Santiago Aparo	5
7	A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC). 2013 ·Journal of Clinical Oncology ·Allyson J. Ocean, Tanios Bekaii‐Saab, Imran Chaudhary, (unknown), Paul J. Christos, (unknown), Erika Florendo, (unknown), Joseph T. Ruggiero, E Popa, Melissa L. Wilson, Mohammad H. Ghalib, (unknown), Umang Shah, Lakshmi Rajdev, (unknown), George M. Gill, Matthew Coffey, Manish A. Shah, Sanjay Goel	9
8	Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: A single institution experience from 1999 to 2010 2013 ·Gynecologic Oncology ·June Y. Hou, Santiago Aparo, Mohammad H. Ghalib, Imran Chaudhary, Umang Shah, Umang Swami, Mark H. Einstein, Gary L. Goldberg, Sridhar Mani, Sanjay Goel	6
9	A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors 2013 ·Investigational New Drugs ·Sharad Ghamande, Chia‐Chi Lin, Daniel C. Cho, Geoffrey I. Shapiro, Eunice L. Kwak, Michael H. Silverman, Yun‐Long Tseng, (unknown), (unknown), (unknown), Teresa A. Coleman, James Chih‐Hsin Yang, Ann‐Lii Cheng, Mohammad H. Ghalib, (unknown), Sanjay Goel	18
10	Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience. 2013 ·Journal of Clinical Oncology ·Umang Shah, Gopichand Pendurti, Umang Swami, (unknown), Mohammad H. Ghalib, Imran Chaudhary, Sridhar Mani, Sanjay Goel, Santiago Aparo	1
11	Reovirus: A Targeted Therapeutic—Progress And Potential 2012 ·Molecular Cancer Research ·Radhashree Maitra, Mohammad H. Ghalib, Sanjay Goel	55
12	Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors. 2012 ·Journal of Clinical Oncology ·Sanjay Goel, Teresa Morán, (unknown), Santiago Viteri, Imran Chaudhary, Mohammad H. Ghalib, Umang Swami, (unknown), Enric Carcereny, (unknown), (unknown), (unknown), Cristina Bugés, Rafael Rosell	2
13	The kinetics of the excision repair cross-complementing group-1 (ERCC1) gene in patients with colorectal cancer. 2012 ·Journal of Clinical Oncology ·(unknown), Atrayee Basu Mallick, Titto Augustine, Imran Chaudhary, (unknown), Radhashree Maitra, (unknown), Santiago Aparo, Raviraja N. Seetharam, Lakshmi Rajdev, Andreas Kaubisch, (unknown), Abdissa Negassa, John M. Mariadason, Mohammad H. Ghalib, Sanjay Goel	1
14	Eribulin—A review of preclinical and clinical studies 2011 ·Critical Reviews in Oncology/Hematology ·Umang Swami, Imran Chaudhary, Mohammad H. Ghalib, Sanjay Goel	78
15	Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·T Ohnuma, J F Holland, (unknown), Eric Wilck, Deborah Lehrer, Mohammad H. Ghalib, Imran Chaudhary, François Wilhelm, Umang Swami, (unknown)	4
16	Phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors. 2010 ·Journal of Clinical Oncology ·Imran Chaudhary, Lakshmi Rajdev, Umang Swami, François Wilhelm, (unknown), Missak Haigentz, Andreas Kaubisch, Shom Goel, Sridhar Mani, Mohammad H. Ghalib	1
17	Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors 2009 ·Investigational New Drugs ·(unknown), Mohammad H. Ghalib, Kavita Desai, Imran Chaudhary, (unknown), Mark H. Einstein, Matthew Coffey, George M. Gill, K.L. Mettinger, John M. Mariadason, Sridhar Mani, Sanjay Goel	116
18	Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer 2008 ·Journal of Clinical Oncology ·Jeffrey M. Vainshtein, Mohammad H. Ghalib, (unknown), Imran Chaudhary, Manoj Maniar, David R. Taft, Stephen C. Cosenza, E. Premkumar Reddy, (unknown), Shalini Mani	5
19	Pharmacodynamic and safety study of reolysin in patients with advanced solid tumors 2007 ·Journal of Clinical Oncology ·(unknown), Keyur Desai, Imran Chaudhary, Mohammad H. Ghalib, (unknown), Mark H. Einstein, Matthew Coffey, George M. Gill, Sridhar Mani, Sanjay Goel	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact